Melinta Therapeutics (MLNT) to Acquire Tetraphase Pharmaceuticals for $39M, plus $16M in CVRs Jun 9, 2020 04:04PM
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals Jun 9, 2020 04:02PM
Melinta Therapeutics Confirms Deerfield as Successful Bidder for Company Mar 4, 2020 04:03PM
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding Feb 25, 2019 08:15AM
Melinta Therapeutics Announces Closing of Initial $75 Million Vatera Convertible Loan Funding Feb 25, 2019 08:15AM


Feb 21, 2019 01:31PM Melinta Therapeutics (MLNT) Board Approves 1-for-5 Reverse Stock Split
Feb 21, 2019 01:30PM Melinta Therapeutics Announces One-for-Five Reverse Stock Split
Feb 21, 2019 01:30PM Melinta Therapeutics Announces One-for-Five Reverse Stock Split
Feb 4, 2019 08:07AM Melinta Therapeutics (MLNT) Provides Updates on Strategic Repositioning Initiatives, Cost Savings Outlook
Feb 4, 2019 08:00AM Melinta Therapeutics Provides Corporate Updates
Feb 4, 2019 08:00AM Melinta Therapeutics Provides Corporate Updates
Nov 29, 2017 07:12AM Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines Comp
Nov 29, 2017 07:05AM Melinta Therapeutics (MLNT) Announces Acquisition of Infectious Disease Business from The Medicines Company (MDCO)
Nov 29, 2017 07:01AM Medicines Co. (MDCO) to Sell its Infectious Disease Business Unit to Melinta Therapeutics (MLNT) for $270M
Nov 29, 2017 07:00AM The Medicines Company Announces Definitive Agreement to Sell its Infectious Disease Business Unit to Melinta Therapeutics
Nov 29, 2017 07:00AM Melinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines Company